Panmure Gordon announced Scancell Holdings PLC (LON:SCLP), holding steady its target price at 68.00GBX today
- Updated: October 9, 2016
Having a price of 17.13GBX, Scancell Holdings PLC (LON:SCLP) traded 3.75% higher on the day. With the last close down -3.30% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Scancell Holdings PLC has recorded a 50-day average of 16.92GBX and a two hundred day average of 17.17GBX. Volume of trade was up over the average, with 397,130 shares of SCLP changing hands over the typical 107,814
Scancell Holdings PLC (LON:SCLP) had its stock price target hold steady to 68.00GBX by Panmure Gordon in an issued report issued 10/10/2016. The updated stock price target indicates a potential upside of 2.97% based on the company's most recent close.
On 09/16/2016, Panmure Gordon released a statement about Scancell Holdings PLC (LON:SCLP) held steady the target price at 68.00GBX that suggested an upside of 3.12%.
Recent Performance Chart
Scancell Holdings PLC has with a 52 week low of 12.00GBX and a one year high of 25.90GBX and has a total market value of 0 GBX.
A total of 1 firm has reported on the stock. 0 firms rating the stock a strong buy, one analyst rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of 68.00GBX.
General Company Details For Scancell Holdings PLC (LON:SCLP)
Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.